share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  08/15 10:52
Moomoo AI 已提取核心信息
TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, has successfully closed a public offering on August 15, 2024, raising $2.0 million in gross proceeds. The offering involved the sale of 23,950 American Depositary Shares (ADSs), Pre-Funded Warrants to purchase up to 1,976,050 ADSs, and Series G Purchase Warrants to purchase up to 2,000,000 ADSs. The Warrants, exercisable immediately and expiring one year from issuance, and the Pre-Funded Warrants, exercisable at any time, were offered at a price of $1.00 per ADS and $0.999 per Pre-Funded Warrant, respectively. This offering was made pursuant to a registration statement on Form F-1, declared effective by the SEC on August 12, 2024. The proceeds are intended to support an upcoming clinical trial for Acute Myeloid Leukemia and for general corporate purposes. Additionally, TC BioPharm has regained compliance with the Nasdaq's minimum stockholders' equity requirement, which was previously below the required threshold as of March 31, 2024. The company had been granted an exception by a Nasdaq Hearings Panel and, following the offering, believes it now meets the equity requirement.
TC BioPharm (Holdings) PLC, a clinical-stage biopharmaceutical company, has successfully closed a public offering on August 15, 2024, raising $2.0 million in gross proceeds. The offering involved the sale of 23,950 American Depositary Shares (ADSs), Pre-Funded Warrants to purchase up to 1,976,050 ADSs, and Series G Purchase Warrants to purchase up to 2,000,000 ADSs. The Warrants, exercisable immediately and expiring one year from issuance, and the Pre-Funded Warrants, exercisable at any time, were offered at a price of $1.00 per ADS and $0.999 per Pre-Funded Warrant, respectively. This offering was made pursuant to a registration statement on Form F-1, declared effective by the SEC on August 12, 2024. The proceeds are intended to support an upcoming clinical trial for Acute Myeloid Leukemia and for general corporate purposes. Additionally, TC BioPharm has regained compliance with the Nasdaq's minimum stockholders' equity requirement, which was previously below the required threshold as of March 31, 2024. The company had been granted an exception by a Nasdaq Hearings Panel and, following the offering, believes it now meets the equity requirement.
临床前生物制药公司TC BioPharm (Holdings) PLC成功于2024年8月15日完成公开发行，募集了200万美元的总收益。该发行涉及出售23,950份美国存托股份（ADS）、可预付款购买高达1,976,050份ADS的预配权证和可购买高达2,000,000份ADS的G系列购买权证。认股证券可立即行使，有效期为自发行之日起一年，每份ADS的发行价格为1.00美元，每份预配权证的发行价格为0.999美元。本次发行是在美国证券交易委员会于2024年8月12日发布的F-1表格注册声明下进行的。所筹集的资金将用于支持急性髓系白血病的即将到来的临床试验和一般公司用途。此外，TC BioPharm已恢复了纳斯达克最低股东权益要求的符合性，此前截至2024年3月31日未达到所需门槛，该公司曾获得纳斯达克听证会面板豁免，并在本次发行后认为已符合股权要求。
临床前生物制药公司TC BioPharm (Holdings) PLC成功于2024年8月15日完成公开发行，募集了200万美元的总收益。该发行涉及出售23,950份美国存托股份（ADS）、可预付款购买高达1,976,050份ADS的预配权证和可购买高达2,000,000份ADS的G系列购买权证。认股证券可立即行使，有效期为自发行之日起一年，每份ADS的发行价格为1.00美元，每份预配权证的发行价格为0.999美元。本次发行是在美国证券交易委员会于2024年8月12日发布的F-1表格注册声明下进行的。所筹集的资金将用于支持急性髓系白血病的即将到来的临床试验和一般公司用途。此外，TC BioPharm已恢复了纳斯达克最低股东权益要求的符合性，此前截至2024年3月31日未达到所需门槛，该公司曾获得纳斯达克听证会面板豁免，并在本次发行后认为已符合股权要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息